Shares of Intrexon Corporation (NYSE:XON) have received a consensus recommendation of “Hold” from the seven brokerages that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $41.00.

Several analysts recently commented on XON shares. BidaskClub downgraded Intrexon Corporation from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Zacks Investment Research downgraded Intrexon Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Finally, Northland Securities set a $30.00 target price on Intrexon Corporation and gave the company a “buy” rating in a research report on Monday, August 7th.

TRADEMARK VIOLATION NOTICE: “Intrexon Corporation (XON) Receives Consensus Rating of “Hold” from Brokerages” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/16/intrexon-corporation-xon-receives-consensus-rating-of-hold-from-brokerages.html.

Shares of Intrexon Corporation (XON) traded up 2.54% during trading on Friday, hitting $19.37. 1,527,015 shares of the stock traded hands. The firm’s market cap is $2.33 billion. Intrexon Corporation has a 52 week low of $17.04 and a 52 week high of $32.90. The company has a 50-day moving average of $19.56 and a 200-day moving average of $21.42.

Intrexon Corporation (NYSE:XON) last posted its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.05. The business had revenue of $54.40 million during the quarter, compared to analyst estimates of $57.17 million. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The company’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.42) EPS. On average, analysts forecast that Intrexon Corporation will post ($0.87) EPS for the current fiscal year.

In related news, Director Robert B. Shapiro acquired 2,850 shares of Intrexon Corporation stock in a transaction on Tuesday, August 22nd. The shares were bought at an average cost of $17.50 per share, with a total value of $49,875.00. Following the completion of the purchase, the director now directly owns 43,157 shares of the company’s stock, valued at approximately $755,247.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Andrew J. Last acquired 2,000 shares of Intrexon Corporation stock in a transaction on Monday, August 14th. The shares were bought at an average cost of $19.99 per share, for a total transaction of $39,980.00. Following the completion of the purchase, the chief operating officer now directly owns 2,000 shares of the company’s stock, valued at $39,980. The disclosure for this purchase can be found here. Insiders purchased 144,569 shares of company stock worth $2,719,429 over the last quarter. 55.10% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of XON. Tower Research Capital LLC TRC grew its stake in shares of Intrexon Corporation by 2,031.7% during the second quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock valued at $125,000 after buying an additional 4,937 shares during the last quarter. Federated Investors Inc. PA bought a new position in shares of Intrexon Corporation during the second quarter valued at approximately $172,000. Pacer Advisors Inc. grew its stake in shares of Intrexon Corporation by 21.6% during the first quarter. Pacer Advisors Inc. now owns 7,352 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 1,305 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Intrexon Corporation during the first quarter valued at approximately $164,000. Finally, Cullinan Associates Inc. bought a new position in shares of Intrexon Corporation during the second quarter valued at approximately $201,000. 82.27% of the stock is currently owned by institutional investors.

About Intrexon Corporation

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Analyst Recommendations for Intrexon Corporation (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.